Organization
New York University Langone Health
4 abstracts
Abstract
Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.Org: Memorial Sloan Kettering Cancer Center, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Columbia University Irving Medical Center, New York, NY, USA, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001).Org: Sarah Cannon Research Institute at HealthONE, Denver, CO, New York University Langone Health, New York, NY, Seagen, Inc.,
Abstract
Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Columbia University Irving Medical Center, New York, NY, USA, New York, NY,
Abstract
Real-world clinical outcomes in a U.S. Asian population with stage IV NSCLC treated with osimertinib (Osi) stratified by EGFR subtype.Org: NYU Langone Health, New York, NY, NYU Grossman School of Medicine, Department of Population Health, New York Oncology Hematology PC, Nykode Therapeutics, New York University School of Medicine,